Brief Title
Expression of Ku70/XRCC6 in Waldenström's Macroglobulinemia
Official Title
Expression of Ku70/XRCC6 and Others NHEJ Components in Waldenström's Macroglobulinemia in Comparison With Others B-cell Lymphoproliferative Disorders and Normal B Cells.
Brief Summary
Waldenström's macroglobulinemia is a rare disease whose pathophysiology remains at present
poorly understood, although a recurrent mutation (L265P MYD88) has recently been described.
Unlike other lymphoproliferative disorders, there is a defect in isotype switching, mechanism
involving AID and NHEJ complex. Using a two-dimensional electrophoresis technology, our group
showed that MW had a specific proteomic profile, and one of the differentially expressed
proteins is Ku70 (encoded by XRCC6 belonging to NHEJ complex) .
The investigators purpose to explore the mechanisms of underexpression of Ku70/XRCC6 (genetic
or epigenetic modification) in comparison with other lymphoid malignancies and normal B
cells.
Study Type
Interventional
Primary Outcome
Measure of ratio Ku70/XRCC6
Condition
Waldenström Macroglobulinemia
Intervention
Blood or bone marrow samples
Study Arms / Comparison Groups
Waldenström macroglobulinemia
Description: Patients with diagnosis of Waldenström macroglobulinemia
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Biological
Estimated Enrollment
55
Start Date
February 2016
Completion Date
July 1, 2020
Primary Completion Date
June 1, 2020
Eligibility Criteria
Inclusion Criteria:
- Patient over 18 years, affiliated to the social regimen
- Written consent collected
MW group :
- Patient with a diagnosis of MW according to WHO criteria (based on the results of
serum protein electrophoresis, bone marrow analysis with immunophenotyping,
cytogenetic analysis and mutation L265P MyD88)
Other SLP :
- Patient with diagnosis of Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma
or Multiple Myeloma
Healthy volunteers :
- volunteers without blood disorders
Exclusion Criteria:
- Women of childbearing age who do not have an effective means of contraception
- Pregnant or nursing
- Demonstration of a kappa or lambda monotype on B lymphocytes
- healthy volunteer with B-cell malignancy
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Contacts
, ,
Location Countries
France
Location Countries
France
Administrative Informations
NCT ID
NCT02640287
Organization ID
2015-A01516-43
Responsible Party
Principal Investigator
Study Sponsor
Central Hospital, Nancy, France
Study Sponsor
, ,
Verification Date
August 2021